SEGMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2025

SCHEDULE OF SEGMENT INFORMATION


	For the Three Months Ended April 30,						For the Six Months Ended April 30,
	2025			2024			2025			2024
Net loss:
Cancer Vaccines	$	(1,879	)	$	(1,713	)	$	(3,897	)	$	(3,469	)
CAR-T Therapeutics		(925	)		(1,444	)		(2,101	)		(2,970	)
Other		(9	)		(23	)		(28	)		(31	)
Total	$	(2,813	)	$	(3,180	)	$	(6,026	)	$	(6,470	)
Net loss	$	(2,813	)	$	(3,180	)	$	(6,026	)	$	(6,470	)

Total operating costs and expenses	$	3,003		$	3,467		$	6,389		$	7,076
Less non-cash stock-based compensation		(988	)		(1,260	)		(2,043	)		(2,520	)
Operating costs and expenses excluding non-cash stock-based compensation	$	2,015		$	2,207		$	4,346		$	4,556

Operating costs and expenses excluding non-cash stock-based compensation:
Cancer Vaccines	$	1,364		$	1,160		$	2,831		$	2,373
CAR-T Therapeutics		643			1,026			1,491			2,154
Other		8			21			24			29
Total	$	2,015		$	2,207		$	4,346		$	4,556
Operating costs and expenses excluding non-cash stock-based compensation	$	2,015		$	2,207		$	4,346		$	4,556

Anixa Biosciences Inc 10-Q